25.56
  Price5.54%   -1.50
(After Hours: 25.56 0 +0.00%)
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
JONES EVAN/ FA Director Jan 11 Option Exercise 4.00 5,000 20,000 43,720
EASTHAM KARIN Director Dec 17 Option Exercise 12.12 5,000 60,600 13,720
EASTHAM KARIN Director Dec 17 Sale 45.00 5,000 225,000 8,720
Anderson Bonnie H Executive Chairwoman Dec 09 Option Exercise 8.86 11,286 99,994 73,542
Kennedy Giulia C Chief Scientific & Med Officer Dec 07 Option Exercise 25.22 6,125 154,481 54,037
Kennedy Giulia C Chief Scientific & Med Officer Dec 07 Sale 40.22 6,125 246,356 47,912
Kennedy Giulia C Chief Scientific & Med Officer Dec 06 Option Exercise 12.52 8,156 102,135 57,144
Kennedy Giulia C Chief Scientific & Med Officer Dec 06 Sale 36.05 9,232 332,784 47,912
EASTHAM KARIN Director Nov 01 Sale 49.09 4,400 215,990 0
Anderson Bonnie H Executive Chairwoman Sep 17 Sale 50.18 2,600 130,478 217,478
Anderson Bonnie H Executive Chairwoman Sep 10 Sale 50.03 1,900 95,050 220,078
Kennedy Giulia C Chief Scientific & Med Officer Sep 08 Sale 50.53 926 46,791 50,049
Kennedy Giulia C Chief Scientific & Med Officer Sep 07 Option Exercise 16.77 12,531 210,154 63,506
Kennedy Giulia C Chief Scientific & Med Officer Sep 07 Sale 50.55 12,531 633,408 50,975
EASTHAM KARIN Director Aug 02 Sale 43.91 4,400 193,194 4,400
Kennedy Giulia C Chief Scientific & Med Officer Jun 23 Option Exercise 24.69 4,375 108,019 56,262
Kennedy Giulia C Chief Scientific & Med Officer Jun 23 Sale 39.75 4,375 173,914 51,887
Kennedy Giulia C Chief Scientific & Med Officer Jun 04 Option Exercise 12.52 8,156 102,135 60,968
Kennedy Giulia C Chief Scientific & Med Officer Jun 04 Sale 34.63 9,081 314,515 51,887
Holstein Jens Director Jun 03 Buy 35.19 2,000 70,389 2,000
Anderson Bonnie H Chairman and CEO May 17 Option Exercise 5.61 14,065 78,905 192,013
EASTHAM KARIN Director May 03 Sale 48.27 4,427 213,700 8,800
Kennedy Giulia C Chief Scientific & Med Officer Mar 04 Option Exercise 18.80 30,970 582,299 105,739
Kennedy Giulia C Chief Scientific & Med Officer Mar 04 Sale 49.36 52,015 2,567,271 53,724
EASTHAM KARIN Director Feb 25 Option Exercise 4.00 6,250 25,000 6,250
EASTHAM KARIN Director Feb 25 Sale 60.70 6,250 379,359 0
Veracyte, Inc. operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. Veracyte, Inc. sells its products through product specialists, institutional managers, account managers, and medical science specialists. Veracyte, Inc. has research collaboration agreement with Loxo Oncology to develop medicines for patients with genetically defined cancers. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Cap:    |  Volume (24h):